[Skip to Navigation]
Views 75
Citations 0
Comment & Response
November 24, 2020

Maternal Docosahexaenoic Acid Supplementation and Bronchopulmonary Dysplasia in Infants—Reply

Author Affiliations
  • 1Department of Pediatrics, Centre Hospitalier Universitaire de Québec–Université Laval, Quebec, Canada
  • 2Department of Endocrinology and Nephrology, Centre Hospitalier Universitaire de Québec–Université Laval, Quebec, Canada
  • 3Division of Neonatology, University of British Columbia, Vancouver, Canada
JAMA. 2020;324(20):2105. doi:10.1001/jama.2020.19410

In Reply Dr van den Akker and colleagues propose a possible explanation linking potential deficits in proresolving lipid mediator synthesis to why DHA failed to improve bronchopulmonary dysplasia in both the N3RO1 and MOBYDIck trials.2 As they mentioned, proresolving lipid mediators D and E resolvin series derived from DHA and eicosapentaenoic acid, respectively, have potent roles in the active regulation of inflammatory processes. Arachidonic acid–derived lipoxins appear particularly important for initiating the resolution of the inflammatory cascade.

×